{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:23:55Z","timestamp":1792416235941,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.phrs.2019.104609","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:53:55Z","timestamp":1576612435000},"page":"104609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":510,"special_numbering":"C","title":["Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update"],"prefix":"10.1016","volume":"152","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104609_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104609_bib0015","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2019.104609_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2019.104609_bib0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2019.104609_bib0030","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104609_bib0035","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104609_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104609_bib0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104609_bib0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2019.104609_bib0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2019.104609_bib0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2019.104609_bib0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pro.5560030203","article-title":"cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer","volume":"3","author":"Madhusudan","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2019.104609_bib0085","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2019.104609_bib0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the conserved internal architecture of a protein kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2019.104609_bib0100","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104609_bib0105","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104609_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2019.104609_bib0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0140","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0150","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0175","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0210","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0215","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2019.104609_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phrs.2019.104609_bib0225","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0230","first-page":"41","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0235","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104609_bib0240","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.bioconjchem.6b00243","article-title":"Bivalent inhibitors of c-Src tyrosine kinase that bind a regulatory domain","volume":"27","author":"Johnson","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: a 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104609_bib0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0255","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0260","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Ann Rep Med Chem"},{"key":"10.1016\/j.phrs.2019.104609_bib0265","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0270","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.104609_bib0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.104609_bib0280","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0285","doi-asserted-by":"crossref","unstructured":"No authors listed. Entrectinib OK\u2019d for cancers with NTRK fusions, NSCLC. Cancer Discov. 2019;9:OF2. doi: 10.1158\/2159-8290.CD-NB2019-101.","DOI":"10.1158\/2159-8290.CD-NB2019-101"},{"key":"10.1016\/j.phrs.2019.104609_bib0290","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104609_bib0295","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","author":"Solomon","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2019.104609_bib0300","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104609_bib0305","article-title":"Larotrectinib: first global approval","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104609_bib0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104609_bib0315","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104609_bib0320","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1358\/dot.2019.55.8.3010573","article-title":"Erdafitinib to treat urothelial carcinoma","volume":"55","author":"Hanna","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2019.104609_bib0325","doi-asserted-by":"crossref","first-page":"24252","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2019.104609_bib0330","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2019.104609_bib0335","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.phrs.2019.104609_bib0340","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fibroblast growth factor 19 signaling as a driver event in hepatocellular carcinoma","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.phrs.2019.104609_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147845","article-title":"Conditional deletion of Fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104609_bib0350","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","author":"Facchinetti","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0355","article-title":"Pexidartinib: first approval","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104609_bib0360","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104609_bib0365","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104609_bib0370","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104609_bib0375","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104609_bib0380","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2019.104609_bib0385","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.phrs.2017.11.015","article-title":"Targeting bromodomain and extraterminal proteins in breast cancer","volume":"129","author":"Sahni","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0390","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.bmcl.2013.06.008","article-title":"2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors","volume":"23","author":"Siu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2019.104609_bib0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2019.104609_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6468(09)04801-2","article-title":"Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design","volume":"48","author":"Smith","year":"2009","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0405","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104609_bib0410","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0415","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104609_bib0420","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.104609_bib0425","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104609_bib0430","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2019.104609_bib0435","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2019.104609_bib0440","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J Chem Inf Compout Sci"},{"key":"10.1016\/j.phrs.2019.104609_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0450","doi-asserted-by":"crossref","unstructured":"K. Bechman, G.B. Galloway, K.L. Winthrop, Small-molecule protein kinase inhibitors and the risk of fungal infections. Curr. Fungal Infect. Rep. https:\/\/doi.org\/10.1007\/s12281-019-00350-w.","DOI":"10.1007\/s12281-019-00350-w"},{"key":"10.1016\/j.phrs.2019.104609_bib0455","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: justum pretium\u2013the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104609_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104291","article-title":"Pharmacological research and cancer: a call to arms","volume":"146","author":"Smalley","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104609_bib0465","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2017.07.004","article-title":"Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care","volume":"55","author":"Yezefski","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.phrs.2019.104609_bib0470","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2019.104609_bib0475","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2019.104609_bib0480","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2019.104609_bib0485","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104609_bib0490","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjmed.2018.05.020","article-title":"Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer","volume":"131","author":"Gilligan","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2019.104609_bib0495","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819328890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819328890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:07:00Z","timestamp":1760911620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819328890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":99,"alternative-id":["S1043661819328890"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104609","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104609"}}